Sodium glucose co-transporter 2 (SGLT2) inhibitors in heart failure with preserved ejection fraction: A systematic review and meta-analysis
Tsampasian, Vasiliki, Elghazaly, Hussein, Chattopadhyay, Rahul Kumar, Ali, Omar, Corballis, Natasha, Chousou, Panagiota Anna, Clark, Allan, Garg, Pankaj and Vassiliou, Vassilios (2022) Sodium glucose co-transporter 2 (SGLT2) inhibitors in heart failure with preserved ejection fraction: A systematic review and meta-analysis. European Journal of Preventive Cardiology, 29 (6). e227–e229. ISSN 2047-4873
![]() |
PDF (F1. CV death or HHF)
- Accepted Version
Restricted to Repository staff only until 1 December 2022. Request a copy |
![]() |
PDF (Accepted_Manuscript)
- Accepted Version
Restricted to Repository staff only until 1 December 2022. Request a copy |
![]() |
PDF (SupplMaterial_Updated)
- Accepted Version
Restricted to Repository staff only until 1 December 2022. Request a copy |
![]() |
Microsoft Word (OpenXML) (Table_updated)
- Accepted Version
Restricted to Repository staff only until 1 December 2022. Request a copy |
Abstract
Whilst heart failure with preserved ejection fraction (HFpEF) is increasingly studied, the search for a single pharmacotherapeutic agent that will improve hard endpoints like hospitalization and mortality still continues.1 Given the various subphenotypes of HFpEF,2 this makes it difficult for a single agent to be universally beneficial. The recent publication of EMPEROR-PRESEVED3 was an instrumental time for an updated meta-analysis focused on sodium glucose co-transporter 2 inhibitors (SGLT2i) use in HFpEF.
Item Type: | Article |
---|---|
Faculty \ School: | Faculty of Medicine and Health Sciences > Norwich Medical School |
Depositing User: | LivePure Connector |
Date Deposited: | 28 Oct 2021 00:49 |
Last Modified: | 13 May 2022 11:30 |
URI: | https://ueaeprints.uea.ac.uk/id/eprint/81902 |
DOI: | 10.1093/eurjpc/zwab189 |
Actions (login required)
![]() |
View Item |